Aromatase inhibition and inactivation

Area of Science:

• Biochemistry
• Endocrinology
• Oncology

Background:

• Aromatase is the key enzyme in estrogen synthesis, converting androstenedione and testosterone to estrone and estradiol.
• Estrogen plays a critical role in stimulating breast cancer growth, making estrogen synthesis inhibition a logical therapeutic strategy.
• Aromatase is an ideal target due to its position as the final step in steroid biosynthesis, minimizing off-target effects.

Purpose of the Study:

• To develop selective aromatase inhibitors for breast cancer treatment.
• To compare the antitumor efficacy of antiestrogens and aromatase inhibitors using a novel animal model.
• To optimize the sequential and combination use of these agents for future clinical trials.

Main Methods:

• Design of substrate analogues based on androstenedione structure to create aromatase inhibitors.
• Development of a unique animal model engrafted with human tumors for efficacy testing.
• Evaluation of enzyme inactivation and high enzyme specificity of developed inhibitors.

Main Results:

• Development of effective aromatase inhibitors, including 4-hydroxyandrostenedione (formestane), which cause enzyme inactivation.
• Demonstration of high enzyme specificity for developed inhibitors.
• Establishment of a preclinical model to guide clinical trial strategies.

Conclusions:

• Aromatase inhibition is a validated and effective strategy for treating estrogen-dependent breast cancers.
• Selective aromatase inhibitors offer a promising therapeutic approach with potential for high specificity.
• Preclinical models are essential for optimizing the use of aromatase inhibitors and antiestrogens in combination therapies.